Lannett Company Inc
F:LN5
Lannett Company Inc
Research & Development
Lannett Company Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lannett Company Inc
F:LN5
|
Research & Development
-$22.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$12.6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Lannett Company Inc
Glance View
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. The company is headquartered in Trevose, Pennsylvania and currently employs 812 full-time employees. The company went IPO on 2002-04-15. The firm's products include Fluphenazine Tablets, which are used for the management of manifestations of psychotic disorders; Posaconazole DR Tablets, which are used to prevent fungal infections in people; Verapamil SR tablets are a calcium channel blocker used in the treatment of high blood pressure, arrhythmia and angina; Methylphenidate CD Capsules used for the treatment of Attention Deficit Hyperactivity Disorder; Omeprazole Capsules, which is indicated for the treatment of certain diseases of the esophagus and stomach ulcers; Pantoprazole Sodium DR Tablets, which is a proton pump inhibitor, indicated for the treatment of certain diseases of the esophagus and pathological hypersecretory conditions; and Sumatriptan Nasal Spray, which is indicated for the acute treatment of migraine attacks.
See Also
What is Lannett Company Inc's Research & Development?
Research & Development
-22.4m
USD
Based on the financial report for Jun 30, 2022, Lannett Company Inc's Research & Development amounts to -22.4m USD.
What is Lannett Company Inc's Research & Development growth rate?
Research & Development CAGR 1Y
7%
Over the last year, the Research & Development growth was 7%.